23andme

The deal values 23andMe at approximately $3.5 billion through the combination of stock and cash financing.
By  Mallory Hackett 11:56 am February 4, 2021
Consumer genomics platform 23andMe is on its way to becoming a publicly-traded company through its merger with VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group. The two companies announced today they have entered into a definitive merger agreement that is expected to close in the second quarter of this year. Once completed, the combined companies’ stock will...
COVID-19 Severity Calculator logo
By  Dave Muoio 03:12 pm January 28, 2021
23andMe's new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company's COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized. 23andMe warned that...
23andMe
By  Laura Lovett 01:23 pm January 4, 2021
After a year of financial struggles, consumer genomics company 23andMe raised just under $82.5 million in equity funding, according to SEC filings. Veteran health tech investors Sequoia Capital and NewView Capital participated in this latest round, according to the Wall Street Journal. Historically, 23andMe has had a number of large investments, including a $300 million investment from pharma...
By  Dave Muoio 03:03 pm August 18, 2020
23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need for confirmatory testing. WHAT HAPPENED This action updates a De Novo approval granted to the consumer genomics company in late 2018. That decision allowed 23andMe to market a test for one of 33...
By  Laura Lovett 04:01 pm January 23, 2020
23andMe has laid off 100 employees across its consumer business, the genomics company confirmed to MobiHealthNews.   This news come amidst disappointing sales numbers, according to CNBC, which first reported the story. In an interview with CNBC’s Chrissy Farr, 23andMe CEO Anne Wojcicki discussed potential factors contributing to what she sees as a market cooldown, top of the list being customers...
By  Dave Muoio 04:11 pm December 11, 2019
Not so fast? Google’s plans to purchase Fitbit will soon be under the US Department of Justice’s lens. According to a New York Post report, the merger raised antitrust flags at both the DOJ and the Federal Trade Commission, with the former federal agency ultimately winning out. The Post’s sources said that both of these agencies are hesitant to allow Google an even greater view into individuals’...
By  Tammy Lovell 06:05 am December 6, 2019
Shoppers may come home with more than they bargained for when visiting Waitrose & Partners Canary Wharf, and John Lewis & Partners, White City. As well as bagging their usual products, customers now have the chance to get a personalised DNA report while browsing the London stores.  Two pop-ups from genetic testing pioneer DnaNudge aim to 'nudge' people into make healthier choices by...

Photo credit: Gabe Ginsberg/Getty Images for LARAS

By  Laura Lovett 02:13 pm September 26, 2019
23andMe, a frontrunner in the consumer genomics space, is turning its attention to clinical trial recruitment. The company has inked a deal with TrialSpark, a health tech platform that lets providers become clinical trial sites, connecting their customers to the latter’s trial network.  The new deal will use 23andMe’s crowdsourced research platform, which lets its customers opt into research and...
By  Dave Muoio 03:36 pm July 11, 2019
Telehealth and mail-order health and wellness consumer brands Hims & Hers have been joined by Dr. Pat Carroll. Formerly a chief medical officer at Walgreens and a 20,000-patient primary care group, Carroll take on a similar role for the growing startup. “Our vision is an ecosystem where people have plenty of options to get the care that’s right for them. Depending on what they need, that...
By  Jonah Comstock 01:36 pm May 20, 2019
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe. MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...